Sökresultat - Portal för medicinska datamodeller (MDM-portal)

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Cardiovascular sub-cohort

- 2021-06-28 - 1 Formulär, 3 Item-grupper, 9 Dataelement, 1 Språk

Item-grupper: Drugs at time of SARS-CoV-2 detection (Baseline), Heart failure, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for the cardiovascular sub-cohort. If a text field can't be filled out, note 'ND'.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Recovery Phase

- 2021-06-28 - 1 Formulär, 15 Item-grupper, 80 Dataelement, 1 Språk

Item-grupper: RC: Respiratory findings, RC: Cardiovascular findings, RC: Neurological findings, RC: Further findings, RC: Vitals, RC: Lung ultrasound, RC: worst chest CT result, RC: Co/Superinfections, RC: Antibacterial treatment: Betalactams, RC: Antibacterial treatment: Macrolides, RC: Antibacterial treatment: Other antibacterial treatment, RC: Multiple sclerosis, severity after COVID-19 infection, RC: Pulmonary function test (Spirometry), RC: Deterioration of prior chronic pulmonary disease, RC: Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for data aggregated in the recovery phase. If a text field can't be filled out, note 'ND'. Criteria of the Recovery Phase: Improvement by at least one phase, i.e. Critical to Complicated or Complicated to Uncomplicated Defervescence Remember: Uncomplicated asymptomatic patients enter recovery phase after 14 days of observation without disease progression No further progression or re-hospitalization

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Baseline I

- 2021-06-24 - 1 Formulär, 39 Item-grupper, 280 Dataelement, 1 Språk

Item-grupper: Sociodemography, Comorbidities, Central nervous system / Neurological disesases, Comorbidities, Cardiovascular diseases, Comorbidities, Pulmonary diseases, Comorbidities, Hematological / oncological diseases, Comorbidities, Rheumatological diseases, Comorbidities, Allergology, Comorbidities, Other internal disorders, Comorbidities, Other conditions, Body-Mass-Index (BMI), Smoking status, Use of e-cigarettes and / or vaporizer?, Pre-existing treatment, Recent immunosuppressive medication, Colonisation with multi-resistant pathogens, Disease limiting life expectancy before positive SARS-CoV-2 testing, Follow-up duration after SARS-CoV-2 diagnosis, Last known status, Diagnosis context, COVID-19 diagnosis details, Complications at baseline: Thrombotic and thromboembolic manifestations, Complications at baseline: Neurological, Complications at baseline: Other severe organ damage, Complications at baseline: Other, Disease course, Duration (days) of..., Symptoms: Please click all symptoms which occurred in the respective clinical phase, Vitals, Lung ultrasound results at SARS-CoV-2 detection, Baseline: Chest CT results at SARS-CoV-2 detection, Heart function, Echocardiography: Ejection fraction (EF) at SARS-CoV-2 detection, Cardiovascular magnetic resonance imaging (CMR) performed in any clinical phase, Neurological diagnostic in various phases, Complementary and/or integrative medicine (CIM) used in any phase, Discussion of limitation of therapy during SARS-CoV-2 infection, Specialist palliative care during SARS-CoV-2 infection, Agreement to share data for scientific purposes, Biomaterial availability for research proposes, Participation in interventional clinical trials

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for baseline information. A related document "Baseline II" documents further baseline information related to baseline timepoint and to disease periods. Baseline / diagnosis is defined as the day the sample of the first positive SARS-CoV-2 result was taken. Please note that only cases with known outcome are collected! If a text field can't be filled out, note 'ND' (for not determined).

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Critical Phase

- 2021-06-23 - 1 Formulär, 32 Item-grupper, 188 Dataelement, 1 Språk

Item-grupper: CR: Cardiovascular findings, CR: Respiratory findings, CR: Other severe organ damage, CR: Fever, CR: Vitals, CR: Lung ultrasound, CR: worst chest CT result, CR: Antivirals, CR: Antibiotics, CR: Antifungals, CR: Immunomodulators, CR: Cardiovascular medication, CR: Non-oral anticoagulants, CR: Oral anticoagulants, CR: Platelet aggregation inhibition, CR: Further anticoagulation / platelet aggregation inhibition, CR: Other COVID-19 related therapy, CR: ICU treatment, CR: Mechanical ventilation, CR: Other extracorporeal support, CR: Co/Superinfections, CR: Antibacterial treatment: Betalactams, CR: Antibacterial treatment: Macrolides, CR: Other antibacterial treatment, CR: Complications, Thrombotic and thromboembolic manifestations, CR: Complications, Neurological, Ischemic stroke: TOAST classification, Ischemic stroke: NIHSS score in acute phase, CR: Complications, Other, Acute kidney injury (KDIGO criteria), CR: SOFA score, CR: Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for data aggregated in the critical phase. If a text field can't be filled out, note 'ND'. Criteria of the Critical Phase: Need for catecholamines Life-threatening cardiac arrhythmia Mechanical ventilation (invasive or non-invasive) Liver failure with Quick< 50% qSOFA >= 2 Renal failure in need of dialysis Remember: The Critical Phase ends as soon as none of the criteria for the Critical Phase is fulfilled anymore AND the patient is free of fever. If the patient has died, it ends with the death of the patient. If the patient has died, do not report terminal, i.e. those recorded after turning off life-support or heart rate "0" after death of the patient.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Complicated Phase

- 2021-06-22 - 1 Formulär, 28 Item-grupper, 155 Dataelement, 1 Språk

Item-grupper: CO: Symptoms / Findings, CO: Feeling of breathlessness, CO: Fever, CO: Vitals, CO: Lung ultrasound, CO: worst chest CT result, CO: Antivirals, CO: Antibiotics, CO: Antifungals, CO: Immunomodulators, CO: Cardiovascular medication, CO: Non-oral anticoagulants, CO: Oral anticoagulants, CO: Platelet aggregation inhibition, CO: Further anticoagulation / platelet aggregation inhibition, CO: Other COVID-19 related therapy, CO: Co/Superinfections, CO: Antibacterial treatment, Betalactams, CO: Antibacterial treatment: Macrolides, CO: Antibacterial treatment: Other antibacterial treatment, CO: Complications, Thrombotic and thromboembolic manifestations, CO: Complications, Neurological, CO, Ischemic stroke: TOAST classification, CO, Ischemic stroke: NIHSS score in acute phase, CO: Complications, Other, CO, Acute kidney injury (KDIGO criteria), CO: SOFA score, CO: Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for data aggregated in the complicated phase. If a text field can't be filled out, note 'ND'. Criteria of the Complicated Phase: Need for oxygen supplementation (In patients with prior oxygen home therapy, clinically meaningful increase in need for oxygenation.) paO2 at room air < 70 mmHg SO2 at room air < 90 % GOT or GPT > 5x ULN New cardiac arrhythmia New pericardial effusion >1cm New heart failure with pulmonary edema, congestive hepatopathy or peripheral edema Remember: The Complicated Phase ends, if none of the criteria for the Complicated Phase is fulfilled anymore AND the patient is free of fever; then move to Recovery Phase. Also, as soon as one of the criteria of the Critical Phase are fulfilled, Complicated Phase ends; move over to Critical Phase. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Uncomplicated Phase

- 2021-06-15 - 1 Formulär, 20 Item-grupper, 120 Dataelement, 1 Språk

Item-grupper: UC: Feeling of breathlessness, UC: Fever, UC: Vital signs, UC: Lung ultrasound, UC: worst chest CT result, UC: Antivirals, UC: Antibiotics, UC: Antifungals, UC: Immunomodulators, UC: Cardiovascular medication, UC: Non-oral anticoagulants, UC: Oral anticoagulants, UC: Platelet aggregation inhibition, UC: Further anticoagulation / platelet aggregation inhibition, UC: Other COVID-19 related therapy, UC: Co/Superinfections, UC: Antibacterial treatment: Betalactams, UC: Antibacterial treatment: Macrolides, UC: Antibacterial treatment: Other antibacterial treatment, UC: Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for data aggregated in the uncomplicated phase. If a text field can't be filled out, note 'ND'. Criteria of the Uncomplicated Phase: Asymptomatic OR Symptoms of upper respiratory tract infection and/or Nausea, emesis, diarrhea and/or Fever Remember: The Uncomplicated Phase ends, if a previously febrile patient has no fever anymore and has completed 14 days of follow-up without entering Complicated or Critical Phase; then move to Recovery Phase. Also, as soon as one of the criteria of the Complicated or Critical Phase are fulfilled, Uncomplicated Phase ends; move over to there. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Diagnostics (General virological and laboratory findings for all phases)

- 2021-06-08 - 1 Formulär, 46 Item-grupper, 320 Dataelement, 1 Språk

Item-grupper: Baseline: SARS-CoV-2, Virological testing types, Baseline: PCR: Site of first detected SARS-CoV-2, Baseline: PCR: Tested target at first positive SARS-CoV-2 testing, BL: PCR pharyngeal swabs at first positive SARS-CoV-2 testing: lowest detected number of PCR cycles, Baseline: Anti-SARS-CoV-2 antibodies (IgG) highest titer measurement, Baseline: Anti-SARS-CoV-2 antibodies (IgA) highest titer measurement, Baseline: Laboratory values, Baseline: Blood Count, Baseline: Other laboratory results, Baseline: Urine test, UC: SARS-CoV-2, Virological testing types, UC: PCR Sites, UC: PCR pharyngeal swab at first positive SARS-CoV-2 testing: lowest detected number of PCR cycles, UC: Viral coinfections, UC: Anti-SARS-CoV-2 antibodies (IgG) highest titer measurement, UC: Anti-SARS-CoV-2 antibodies (IgA) highest titer measurement, UC: Laboratory values, UC: Blood count, UC: Other laboratory results, CO: SARS-CoV-2, Virological testing, CO: PCR Sites, CO: PCR pharyngeal swab at first positive SARS-CoV-2 testing: lowest detected number of PCR cycles, CO: Viral coinfections, CO: Anti-SARS-CoV-2 antibodies (IgG) highest titer measurement, CO: Anti-SARS-CoV-2 antibodies (IgA) highest titer measurement, CO: Laboratory values, CO: Blood count, CO: Other laboratory results, CR: SARS-CoV-2, Virological testing types, CR: PCR Sites, CR: PCR pharyngeal swabs at first positive SARS-CoV-2 testing: lowest detected number of PCR cycles, CR: Viral coinfections, CR: Anti-SARS-CoV-2 antibodies (IgG) highest titer measurement, CR: Anti-SARS-CoV-2 antibodies (IgA) highest titer measurement, CR: Laboratory values, CR: Blood count, CR: Other laboratory results, RC: SARS-CoV-2, Virological testing types, RC: PCR Sites, RC: PCR pharyngeal swabs at first positive SARS-CoV-2 testing: lowest detected number of PCR cycles, RC: Anti-SARS-CoV-2 antibodies (IgG) highest titer measurement, RC: Anti-SARS-CoV-2 antibodies (IgA) highest titer measurement, RC: Laboratory values, RC: Blood count, RC: Other laboratory results, Diagnostics: Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for general virological and laboratory findings at baseline and aggregated for all phases. If a text field can't be filled out, note 'ND'. Please keep in mind that the clinical phases represent time intervals while the baseline is a point in time. Data input of baseline and the clinical phase at diagnosis can but do not have to be identical.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Neurological sub-cohort

- 2021-05-27 - 1 Formulär, 24 Item-grupper, 156 Dataelement, 1 Språk

Item-grupper: Duration of neurological comorbidity, Neurological medication before SARS-CoV-2 infection, Neurological status, Specification of neurological comorbidities, Cerebrovascular disease, Cerebrovascular disease: Medication, Multiple Sclerosis subtype & severity, Multiple Sclerosis: Immunomodulatory medication at Baseline, MS: Immunosuppression discontinuation in context of COVID-19, Recent MS relapse treatment, Neurodegeneration, Cognitive / neuropsychiatric impairment during COVID-19 infection, Visual impairment during COVID-19, Oculomotoric impairment during COVID-19 infection, Paresis during COVID-19 infection, Abnormal muscle reflexes during COVID-19 infection, Sensory deficit during COVID-19 infection, Other neurological findings during COVID-19 infection, Neurological diagnostics; Imaging, Neurological diagnostics: EEG, Neurological diagnostics: Electrophysiology, Neurological diagnostics: Spinal tap, Neurological diagnostics: Spinal tap - pathogens, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for the neurological sub-cohort. If a text field can't be filled out, note 'ND'.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Nephrological sub-cohort

- 2021-05-27 - 1 Formulär, 5 Item-grupper, 17 Dataelement, 1 Språk

Item-grupper: AKI, CKD, CKD etiology, Dialysis, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for the nephrological sub-cohort. If a text field can't be filled out, note 'ND'.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Solid organ transplant sub-cohort

- 2021-05-11 - 1 Formulär, 6 Item-grupper, 31 Dataelement, 1 Språk

Item-grupper: Type of functioning organ transplant, Most recent transplantation, Immunsuppression at diagnosis of SARS-CoV-2, Graft status before COVID-19, Therapeutic measures of transplant specific therapy, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for the solid organ transplant sub-cohort. All questions refer to the day of diagnosis (diagnosis means first positive virus result). Please note that only cases with known outcome are collected at LEOSS!

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Immunosuppressive premedication

- 2021-05-07 - 1 Formulär, 31 Item-grupper, 90 Dataelement, 1 Språk

Item-grupper: Antibodies: Anti-CD20, Antibodies: CD-22, Antibodies: CD-38, Antibodies: CD-52, Antibodies: Anti-CD79b, Antibodies: BLyS, Antibodies: CD19-BiTE, Antibodies: Complement inhibitors, Antibodies: Integrin antagonists, Antibodies: Interleukin inhibitors, Antibodies: TNF-alpha inhibitors, Other Antibodies, Inhibitors: Co-stimulation inhibitors, Inhibitors: Calcineurin inhibitors, Inhibitors: Interleukin inhibitor, Inhibitors: JAK inhibitors, Inhibitors: mTOR inhibitors, Inhibitor: PDE-4-inhibitor, Other Inhibitors, Recent: Checkpoint inhibitors, Chemotherapeutics: Antimetabolites, Chemotherapeutics: Cytostatics, Other Chemotherapeutics, Corticosteroids, Other immunosuppressive regimens: Fumarate, Other immunosuppressive regimens: Immunoglobulines, Other immunosuppressive regimens: Interferon, Immunosuppressive regimens: Other Multiple Sclerosis drugs, Other immunosuppressive regimens, Immunosuppressive drugs: Underlying disease, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for immunosuppressive premedication. If a text field can't be filled out, note 'ND'.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Cardiac MRI (CMR) details

- 2021-05-07 - 1 Formulär, 17 Item-grupper, 89 Dataelement, 1 Språk

Item-grupper: Clinical phase of CMR diagnostic, CMR Indication, CMR context, Patient's characteristics, Heart Rhythm, CMR procedure completed, MRI: Delayed contrast enhancement, CMR measurements, Mapping results, Edema T2 on T2-weighted imaging, Wall motion abnormalities, Perfusion deficit during stress testing, Pericardium, Myocardial strain, Assessment, CMR: Additional information, CMR_completed

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for cardiac MRI (CMR) details. If a text field can't be filled out, note 'ND'.

Nyckelord

Innehållsförteckning

Valda datamodeller